Compare Stocks: BNBX, CLGN, RNAZ, and BDRX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BDRX Biodexa Pharmaceuticals	$1.52	$2.30	$1.02 ▼ $59.40	$1.57M	1.24	269,467 shs	10,391 shs
BNBX Applied Dna Sciences	$0.15	$0.27	$0.07 ▼ $7.15	$1.04M	0.6	484,908 shs	88,013 shs
CLGN CollPlant Biotechnologies	$0.33	$0.34	$0.27 ▼ $3.18	$4.76M	1.67	62,493 shs	70,819 shs
RNAZ TransCode Therapeutics	$3.28	$6.00	$3.21 ▼ $20.99	$3.48M	1.24	19,153 shs	40,808 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BDRX Biodexa Pharmaceuticals	0.00%	-1.30%	-28.64%	-51.75%	-95.68%
BNBX Applied Dna Sciences	0.00%	-6.45%	+21.34%	-66.32%	+14,499,900.00%
CLGN CollPlant Biotechnologies	0.00%	-2.69%	-1.58%	-24.17%	-87.07%
RNAZ TransCode Therapeutics	0.00%	-17.17%	-61.09%	-46.84%	-69.60%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BDRX Biodexa Pharmaceuticals	$1.52	$2.30	$1.02 ▼ $59.40	$1.57M	1.24	269,467 shs	10,391 shs
BNBX Applied Dna Sciences	$0.15	$0.27	$0.07 ▼ $7.15	$1.04M	0.6	484,908 shs	88,013 shs
CLGN CollPlant Biotechnologies	$0.33	$0.34	$0.27 ▼ $3.18	$4.76M	1.67	62,493 shs	70,819 shs
RNAZ TransCode Therapeutics	$3.28	$6.00	$3.21 ▼ $20.99	$3.48M	1.24	19,153 shs	40,808 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BDRX Biodexa Pharmaceuticals	0.00%	-1.30%	-28.64%	-51.75%	-95.68%
BNBX Applied Dna Sciences	0.00%	-6.45%	+21.34%	-66.32%	+14,499,900.00%
CLGN CollPlant Biotechnologies	0.00%	-2.69%	-1.58%	-24.17%	-87.07%
RNAZ TransCode Therapeutics	0.00%	-17.17%	-61.09%	-46.84%	-69.60%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BDRX Biodexa Pharmaceuticals	1.00	Sell	N/A	N/A
BNBX Applied Dna Sciences	1.00	Sell	N/A	N/A
CLGN CollPlant Biotechnologies	2.00	Hold	$11.50	3,388.02% Upside
RNAZ TransCode Therapeutics	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest BNBX, CLGN, RNAZ, and BDRX Analyst Ratings

Date	Company	Brokerage	Action	Rating
7/17/2026	RNAZ TransCode Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/18/2026	BDRX Biodexa Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
6/8/2026	CLGN CollPlant Biotechnologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
6/3/2026	BDRX Biodexa Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)
5/22/2026	CLGN CollPlant Biotechnologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)

(Data available from 8/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BDRX Biodexa Pharmaceuticals	$470K	3.33	N/A	N/A	$110.30 per share	0.01
BNBX Applied Dna Sciences	$2.09M	0.50	N/A	N/A	$1.50 per share	0.10
CLGN CollPlant Biotechnologies	$2.37M	2.01	N/A	N/A	$0.48 per share	0.69
RNAZ TransCode Therapeutics	N/A	N/A	N/A	N/A	$11.27 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BDRX Biodexa Pharmaceuticals	-$8.42M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	9/11/2026 (Estimated)
BNBX Applied Dna Sciences	-$15.16M	-$36.76	N/A	N/A	N/A	-1,647.25%	-349.95%	-283.96%	N/A
CLGN CollPlant Biotechnologies	-$11.49M	-$1.45	N/A	N/A	N/A	-683.68%	-218.81%	-139.28%	8/20/2026 (Estimated)
RNAZ TransCode Therapeutics	-$34.66M	-$52.37	N/A	N/A	N/A	N/A	-1,027.46%	-41.16%	8/18/2026 (Estimated)

Latest BNBX, CLGN, RNAZ, and BDRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/20/2026	Q2 2026	CLGN CollPlant Biotechnologies	-$0.2448	N/A	N/A	N/A	$0.48 million	N/A
8/14/2026	Q2 2026	RNAZ TransCode Therapeutics	N/A	-$7.17	N/A	-$7.17	N/A	N/A
8/13/2026	Q3 2026	BNBX Applied Dna Sciences	N/A	-$0.57	N/A	-$0.57	N/A	$0.61 million
5/30/2026	Q1 2026	CLGN CollPlant Biotechnologies	-$0.2374	-$0.23	+$0.0074	-$0.23	$0.46 million	$0.07 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BDRX Biodexa Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BNBX Applied Dna Sciences	N/A	N/A	N/A	N/A	N/A
CLGN CollPlant Biotechnologies	N/A	N/A	N/A	N/A	N/A
RNAZ TransCode Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BDRX Biodexa Pharmaceuticals	N/A	2.03	2.03
BNBX Applied Dna Sciences	N/A	1.82	1.74
CLGN CollPlant Biotechnologies	N/A	2.27	1.99
RNAZ TransCode Therapeutics	N/A	3.11	3.11

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BDRX Biodexa Pharmaceuticals	17.51%
BNBX Applied Dna Sciences	22.22%
CLGN CollPlant Biotechnologies	21.69%
RNAZ TransCode Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
BDRX Biodexa Pharmaceuticals	0.34%
BNBX Applied Dna Sciences	6.14%
CLGN CollPlant Biotechnologies	9.60%
RNAZ TransCode Therapeutics	0.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BDRX Biodexa Pharmaceuticals	20	1.03 million	1.03 million	Not Optionable
BNBX Applied Dna Sciences	70	7.20 million	6.76 million	N/A
CLGN CollPlant Biotechnologies	70	14.44 million	13.05 million	Optionable
RNAZ TransCode Therapeutics	9	1.06 million	1.06 million	Not Optionable

BNBX, CLGN, RNAZ, and BDRX Headlines

Recent News About These Companies

Virax Biolabs and Transcode Therapeutics Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV

August 7, 2026 | finance.yahoo.com

TransCode Therapeutics, Inc.

July 22, 2026 | edition.cnn.com

TransCode Therapeutics Inc RNAZ

July 3, 2026 | morningstar.comM

TransCode Therapeutics, Inc. (RNAZ) Discusses Strategic, Scientific, and Clinical Updates With Focus on TTX-MC138 Phase 2a Trial in Colorectal Cancer Prepared Remarks Transcript

June 18, 2026 | seekingalpha.com

RNAZ: Introducing RNA therapeutics

June 8, 2026 | msn.com

TransCode Therapeutics to Host R&D Webcast on June 18, 2026

June 8, 2026 | prnewswire.com

RNAZ Share News Today

June 4, 2026 | uk.investing.com

EXCLUSIVE: TransCode's RNA Therapeutic Achieves 64% Stable Disease Rate In Colorectal Cancer Phase 1 Study

June 3, 2026 | finance.yahoo.com

TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer

June 3, 2026 | prnewswire.com

TransCode Therapeutics, Inc.: TransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal Cancer

May 28, 2026 | finanznachrichten.de

TransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal Cancer

May 27, 2026 | prnewswire.com

TransCode Therapeutics Appoints Dr. Anna Moore as Chair of Scientific Advisory Board; Announces Sponsored Research Agreement with Michigan State University

April 27, 2026 | prnewswire.com

TransCode Therapeutics signs financing deal worth up to $20 million

April 8, 2026 | msn.com

TransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company's Runway into Late 2027/Early 2028

April 7, 2026 | prnewswire.com

TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer Patients

March 3, 2026 | prnewswire.com

TransCode Therapeutics Announces Publication of Preclinical Testing of RIG-I Immunotherapeutic Candidate Supporting Further Development

February 23, 2026 | prnewswire.com

TransCode Therapeutics Advances Phase 2a Colorectal Cancer Trial

February 11, 2026 | theglobeandmail.com

TransCode Therapeutics, Inc.: TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138

February 5, 2026 | finanznachrichten.de

TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138

February 5, 2026 | prnewswire.com

TransCode Therapeutics reports promising preclinical glioblastoma results

January 6, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNBX, CLGN, RNAZ, and BDRX Company Descriptions

Biodexa Pharmaceuticals NASDAQ:BDRX

$1.52 0.00 (0.00%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$1.51 -0.01 (-0.92%)

As of 08/14/2026 07:41 PM Eastern

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Applied Dna Sciences NASDAQ:BNBX

$0.14 0.00 (0.00%)

As of 08/14/2026 03:53 PM Eastern

Applied DNA Sciences, Inc. develops and markets DNA-based technology solutions for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets; and for supply chain security, anti-counterfeiting, and anti-theft technology purposes. The company's supply chain security and product authentication solutions include SigNature molecular tags that provide forensic power and protection for various applications used to fortify brand protection efforts and strengthen supply chain security, as well as mark, track, and convict criminals; SigNify IF portable DNA readers and SigNify consumable reagent test kits that provide real-time authentication of molecular tags in the field; and CertainT, which indicates the use of tagging, testing, and tracking platforms and solutions enabling manufacturers, brands, and trade organizations to convey proof of their product claims. It also manufactures and sells COVID-19 PCR-based molecular diagnostic test kit under the LineaTM COVID-19 Assay Kit trademark; and COVID-19 diagnostic test kit to prevent virus spread within a community, school, or workplace under the safeCircle trademark. In addition, the company provides preclinical contract research and manufacturing services for the nucleic acid-based therapeutic markets; and contract research services to RNA based drug and biologic customers for preclinical studies. Further, it develops an invasive circulating tumor cell capture and identification technology that uses a patented functional assay to capture live invasive circulating tumor cell and associated lymphocytes. The company operates in the United States, Europe, Asia, and internationally. The company was formerly known as Datalink Systems, Inc. and changed its name to Applied DNA Sciences, Inc. in 2002. Applied DNA Sciences, Inc. was founded in 1983 and is headquartered in Stony Brook, New York.

CollPlant Biotechnologies NASDAQ:CLGN

$0.33 0.00 (0.00%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$0.33 +0.00 (+0.09%)

As of 08/14/2026 07:57 PM Eastern

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; as well as develops injectable breast implants and 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures. It has collaboration agreements with Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; International Society for Biofabrication; AbbVie; and STEMCELL Technologies. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. The company was founded in 2004 and is headquartered in Rehovot, Israel.

TransCode Therapeutics NASDAQ:RNAZ

$3.28 0.00 (0.00%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$3.42 +0.14 (+4.27%)

As of 08/14/2026 07:34 PM Eastern

TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BNBX, CLGN, RNAZ, and BDRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BNBX, CLGN, RNAZ, and BDRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BNBX, CLGN, RNAZ, and BDRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNBX, CLGN, RNAZ, and BDRX Company Descriptions

Biodexa Pharmaceuticals NASDAQ:BDRX

Applied Dna Sciences NASDAQ:BNBX

CollPlant Biotechnologies NASDAQ:CLGN

TransCode Therapeutics NASDAQ:RNAZ

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BNBX, CLGN, RNAZ, and BDRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BNBX, CLGN, RNAZ, and BDRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BNBX, CLGN, RNAZ, and BDRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNBX, CLGN, RNAZ, and BDRX Company Descriptions

Biodexa Pharmaceuticals NASDAQ:BDRX

Applied Dna Sciences NASDAQ:BNBX

CollPlant Biotechnologies NASDAQ:CLGN

TransCode Therapeutics NASDAQ:RNAZ

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools